Method for manufacturing glycoproteins having human-type glycosylation
The present invention provides a method for manufacturing a glycoprotein having a human-type sugar chain comprising a step in which transformed plant cell is obtained by introducing to a plant cell the gene of glycosyltransfetase and the gene of an exogenous glycoprotein, and a step in which the obtained transformed plant cell is cultivated.
1. A plant-produced glycoprotein having a human-type sugar chain, obtained from a transformed plant cell, wherein the transformed plant cell was produced by: introducing to a plant cell a gene encoding a galactosyltransferase enzyme and a gene of an exogenenous glycoprotein; cultivating the transformed plant cell; and when desired separating the resulting glycoprotein.
2. The glycoprotein according to claim 1 , wherein the galactosyltransferase enzyme transfers a galactose residue to a non-reducing terminal acetylglucosamine residue.
3. The glycoprotein according to claim 1 , wherein the glycoprotein with a human-type sugar chain comprises a core sugar chain and an outer sugar chain, wherein the core sugar chain comprises a plurality of mannose and acetylglucosamine, and wherein the outer sugar chain contains a terminal sugar chain portion with a non-reducing terminal galactose.
4. The glycoprotein according to claim 3 , wherein the outer sugar chain has a straight chain configuration.
5. The glycoprotein according to claim 3 , wherein the outer sugar chain has a branched chain configuration.
6. The glycoprotein according to claim 5 , wherein the branched sugar chain portion has a mono-, bi-, tri, or tetra-configuration.
7. The glycoprotein according to claim 3 , wherein the glycoprotein produced contains no fucose or xylose linked to one or more of the core sugar chain, the outer sugar chain and the terminal sugar chain.
8. The glycoprotein according to claim 1 wherein the gene encoding an exogenous glycoprotein is selected from one or more of the group consisting of enzymes, hormones, cytokines, antibodies, vaccines, receptors and serum proteins.
9. The glycoprotein according to claim 8 , wherein the exogenous glycoprotein encoded by the introduced gene is an enzyme selected from one or more of the group consisting of horseradish peroxidase, kinase, glucocerebrosidase, α-galactosidase, tissue-type plasminogen activator (TPA), and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
10. The glycoprotein according to claim 8 , wherein the exogenous glycoprotein encoded by the introduced gene is a hormone or cytokine selected from one or more of the group consisting of enkephalin, interferon-alpha, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (C-CSF), chorion stimulating hormone, interleukin-2, interferon-beta, interferon-gamma, erythropoietin, vascular endothelial growth factor, human choriogonadotropin (HCG), leuteinizing hormone (LH), thyroid stimulating hormone (TSH), prolactin, and ovary stimulating hormone.
11. The glycoprotein according to claim 8 , wherein the exogenous glycoprotein encoded by the introduced gene is an antibody selected from immunoglobulin G (IgG) or single chain variable region antibody fragments (scFV).
12. The glycoprotein according to claim 1 or 3 wherein the sugar chain is a human-type sugar chain.
13. A plant-produced glycoprotein comprising no fucose or xylose linked to one or more of the core sugar chain, the outer sugar chain and the terminal sugar chain.